AtriCure receives CE-Mark for the EnCompass Clamp

AtriCure announced that it has received regulatory approval to sell the EnCompass Clamp in CE-marked countries in the European Union, and European surgeons have recently performed the first series of cases with AtriCure’s EnCompass Clamp. The EnCompass Clamp received FDA 510 K clearance and was launched in the United States in 2022. “Launching our EnCompass Clamp in Europe represents a significant expansion of our product line internationally,” said Michael Carrel, President and CEO of AtriCure. “We have seen this product have a positive impact in the United States over the last two years by advancing treatment concomitant to cardiac surgery. We are excited to offer this safe, innovative, and effective therapy to patients and our physician partners in Europe.”